XKRX
140410
Market cap1.56bUSD
Oct 08, Last price
69,000.00KRW
1D
2.22%
1Q
21.91%
Jan 2017
200.00%
IPO
268.98%
Name
Mezzion Pharma Co Ltd
Chart & performance
P/E
—
P/S
265.13
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.14%
Rev. gr., 5y
-22.69%
Revenues
7.91b
-8.15%
Net income
-34.93b
L+79.34%
CFO
-16.59b
L-10.28%
Dividend
Dec 27, 201275 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mezzion Pharma Co., Ltd. operates as a pharmaceutical enterprise focused on the discovery, production, and licensing of various medical treatments. The company's therapeutic offerings target conditions such as erectile dysfunction, benign prostatic hyperplasia, and Fontan disease. Established by Park, Dong-Hyun on September 25, 2002, its corporate base is located in Seoul, South Korea.
Key people
Beom Jin Choi
Director · since 2024
Peter Manso
Director
Dong Hyeon Park
Chief Executive Officer, Director
Director
James Yeager
Director
Jin Su Yim
Director
Jeong Seok Chae
Non-Executive Independent Director
Bon Gwon Gu
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||